US · MDXH
MDxHealth S.A.
Price · as of 2026-10-31
$0.16
Market cap 22.27M
Price history
The price history chart is shown only to users with a Pro subscription.
InvestorsCraft valuation
Fair value (AI, DCF / IC, Graham) for MDxHealth S.A. (MDXH) is available to Pro members and via the machine API.
- AI valuation — available
- Intrinsic / IC value — available
- Upside vs price — available
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
The valuation history chart is shown only to users with a Pro subscription.
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Historic valuation ratios are shown only to users with a Pro subscription.
Line items
Line items
Line items
About MDxHealth S.A.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
- CEO
- Michael K. McGarrity
- Employees
- 364
- Beta
- 0.38
The peer comparison table is shown only to users with a Pro subscription.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice.